+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Mannkind Corporation - logo

MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of therapeutic products for patients with diseases such as diabetes. Its lead product is AFREZZA, a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. MannKind Corporation has license and collaboration agreement with Sanofi-Aventis Deutschland GmbH for the development of AFREZZA. The company was founded in 1991 and is headquartered in Valencia, California.

From
From
From
From
From
Glucagon-like Peptide 1 Global Market Report 2024 - Product Thumbnail Image

Glucagon-like Peptide 1 Global Market Report 2024

  • Report
  • January 2024
  • 200 Pages
  • Global
From
Insulin Pump Market - Global Outlook and Forecast 2023-2028 - Product Thumbnail Image

Insulin Pump Market - Global Outlook and Forecast 2023-2028

  • Report
  • March 2023
  • 279 Pages
  • Global
From
From
Anaphylaxis - Pipeline Insight, 2024 - Product Thumbnail Image

Anaphylaxis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
From
Insulin Pump Market 2024-2028 - Product Thumbnail Image

Insulin Pump Market 2024-2028

  • Report
  • September 2024
  • 158 Pages
  • Global
From
From
Needle-Free Devices: Technologies and Global Markets - Product Thumbnail Image

Needle-Free Devices: Technologies and Global Markets

  • Report
  • March 2019
  • 170 Pages
  • Global
From
Loading Indicator